23andMe’s (ME) “Sell (E+)” Rating Reiterated at Weiss Ratings

23andMe (NASDAQ:ME)‘s stock had its “sell (e+)” rating restated by equities researchers at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

23andMe Price Performance

NASDAQ:ME opened at $2.72 on Wednesday. The company has a market cap of $72.98 million, a PE ratio of -0.18 and a beta of 1.14. 23andMe has a one year low of $2.42 and a one year high of $14.40. The firm’s 50 day simple moving average is $3.22 and its 200 day simple moving average is $4.68.

23andMe (NASDAQ:ME) last issued its quarterly earnings results on Tuesday, January 28th. The company reported ($1.02) earnings per share for the quarter. 23andMe had a negative net margin of 183.39% and a negative return on equity of 170.07%.

Institutional Trading of 23andMe

Institutional investors have recently bought and sold shares of the company. GSA Capital Partners LLP bought a new position in shares of 23andMe in the 3rd quarter worth about $805,000. FMR LLC boosted its stake in 23andMe by 24.0% during the 3rd quarter. FMR LLC now owns 993,848 shares of the company’s stock valued at $345,000 after purchasing an additional 192,099 shares during the last quarter. Geode Capital Management LLC boosted its stake in 23andMe by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,246,093 shares of the company’s stock valued at $1,476,000 after purchasing an additional 28,252 shares during the last quarter. FNY Investment Advisers LLC acquired a new position in 23andMe during the 4th quarter valued at about $26,000. Finally, MassMutual Private Wealth & Trust FSB bought a new position in shares of 23andMe during the 4th quarter worth approximately $40,000. Institutional investors own 36.10% of the company’s stock.

About 23andMe

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.